

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**WEGO 威高**

**山東威高集團醫用高分子製品股份有限公司**

**Shandong Weigao Group Medical Polymer Company Limited \***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1066)**

## **ANNOUNCEMENT**

### **PRINCIPAL FINANCIAL DATA OF WEIGAO ORTHOPAEDIC FOR THE SIX MONTHS ENDED 30 JUNE 2021**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”) dated 26 August 2021 (the “**Announcement**”) in relation to the 2021 interim report for the six months ended 30 June 2021 (the “**Reporting Period**”) of Shandong Weigao Orthopaedic Device Company Limited (“**Weigao Orthopaedic**”), a subsidiary of the Company and whose shares are listed on the science and technology innovation board on the Shanghai Stock Exchange (stock code: 688161).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of Weigao Orthopaedic for the six months ended 30 June 2021 as set out in the Announcement.

\* *For identification purpose only*

## PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF WEIGAO ORTHOPAEDIC

*Unit: Yuan*

*Currency: RMB*

	As at the end of this Reporting Period	As at the end of last year	Increase/decrease at the end of this Reporting Period as compared with the end of last year (%)
Total assets	5,102,408,522.03	3,174,596,918.79	60.73
Net assets attributable to shareholders of the listed company	4,226,642,447.00	2,453,797,254.33	72.25
	<b>During this Reporting Period</b>	<b>The same period of last year</b>	<b>Increase/decrease for this Reporting Period as compared with the same period of last year (%)</b>
Turnover	1,095,315,818.33	831,977,639.24	31.65
Net profit attributable to shareholders of the listed company	369,150,481.23	267,787,225.93	37.85
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	364,168,048.28	249,871,389.85	45.74
Net cash flow arising from operating activities	407,784,522.96	361,675,695.44	12.75
Weighted average return on net assets (%)	13.99	13.35	Increased by 0.64 percentage point
Basic earnings per share (Yuan/Share)	1.03	0.75	37.33
Diluted earnings per share (Yuan/Share)	1.03	0.75	37.33
Research and development investment as a percentage of turnover (%)	4.66	4.05	Increased by 0.61 percentage point

By Order of the Board

**Shandong Weigao Group Medical Polymer Company Limited**

**Long Jing**

*Chairman*

WeiHai, Shandong, the PRC, 26 August 2021

*As at the date hereof, the Board comprises of:*

Mr. Long Jing (*Executive Director*)

Mr. Cong Rinan (*Executive director*)

Mr. Tang Zhengpeng (*Non-executive Director*)

Mr. Chen Lin (*Non-executive Director*)

Mr. Lian Xiaoming (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mrs. Fu Mingzhong (*Independent non-executive Director*)

Mrs. Wang Jinxia (*Independent non-executive Director*)

\* *For identification purpose only*